NEW YORK, NY, June 04, 2020 (GLOBE NEWSWIRE) — ARYA Sciences Acquisition Corp II (the “Firm”), a particular goal acquisition firm fashioned for the aim of getting into into a mixture with a number of companies or entities, right now introduced the pricing of its preliminary public providing of 13,000,00Zero items at a value of $10.00 per unit. The items shall be listed on The Nasdaq Capital Market (“Nasdaq”) and commerce underneath the ticker image “ARYBU” starting on June 5, 2020. Every unit consists of 1 Class A odd share of the Firm and one-third of 1 redeemable warrant. Every entire warrant entitles the holder thereof to buy one Class A odd share of the Firm at a value of $11.50 per share. As soon as the securities comprising the items start separate buying and selling, the Class A odd shares and warrants are anticipated to be listed on Nasdaq underneath the symbols “ARYB” and “ARYBW,” respectively.
Whereas the Firm could pursue an preliminary enterprise mixture goal in any enterprise or business, it intends to give attention to the healthcare business in america and different developed nations. The Firm intends to give attention to goal companies with valuations of $300 to $500 million or extra and which have the potential to be $1 billion or extra market capitalization firms. The Firm is led by Chairman Joseph Edelman, Chief Government Officer Adam Stone, Chief Monetary Officer Michael Altman and Chief Enterprise Officer Konstantin Poukalov.
Jefferies LLC and Goldman Sachs & Co. LLC are serving as joint book-running managers for the providing. The Firm has granted the underwriters a 45-day choice to buy as much as a further 1,950,00Zero items to cowl over-allotments, if any, on the preliminary public providing value.
The providing is being made solely via a prospectus. When obtainable, copies of the prospectus could also be obtained from: Jefferies LLC, Attn: Fairness Syndicate Prospectus Division, 520 Madison Avenue, 2nd Flooring, New York, NY 10002, by phone: 877-821-7388 or by e-mail: Prospectus_Department@Jefferies.com; or Goldman Sachs & Co. LLC, Attn: Prospectus Division, 200 West Road, New York, New York 10282, phone: (212) 902-1171 or e-mail: Prospectusemail@example.com.
The registration statements regarding the securities grew to become efficient on June 4, 2020. This press launch shall not represent a suggestion to promote or the solicitation of a suggestion to purchase, nor shall there be any sale of those securities in any state or jurisdiction wherein such supply, solicitation or sale can be illegal previous to registration or qualification underneath the securities legal guidelines of any such state or jurisdiction.
The providing is anticipated to shut on June 9, 2020, topic to customary closing circumstances.
Cautionary Notice Regarding Ahead-Wanting Statements
This press launch accommodates statements that represent “forward-looking statements,” together with with respect to the proposed preliminary public providing and the anticipated use of the web proceeds. No assurance will be on condition that the providing mentioned above shall be accomplished on the phrases described, or in any respect, or that the web proceeds of the providing shall be used as indicated. Ahead-looking statements are topic to quite a few circumstances, a lot of that are past the management of the Firm, together with these set forth within the Threat Elements part of the Firm’s registration assertion and preliminary prospectus for the Firm’s providing filed with the Securities and Trade Fee (the “SEC”). Copies can be found on the SEC’s web site, www.sec.gov. The Firm undertakes no obligation to replace these statements for revisions or modifications after the date of this launch, besides as required by legislation.
Chief Monetary Officer of ARYA Sciences Holdings Corp II